Published : 02/28/2023 - Categories : News
Alsachim is proud to add the [13C,2H3]-Lenacapavir labeled standard to its product catalogue. This new antiretroviral is the outcome of a strong R&D and synthesis work done by Alsachim teams.
A stable isotope labeled antiviral
Recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), Lenacapavir is indicated for the treatment of adults with multidrug-resistant HIV-1 infection for whom a suppressive antiretroviral therapy program is not otherwise feasible.
As early as December 2022, in its own laboratories, Alsachim’s experts started a research and development process for the new antiretroviral to determine the reaction scheme, identify the best labelling method and perform the different steps necessary to obtain this new target molecule.
Being attentive to its market, Alsachim has been able to identify and mobilize all the knowledge and resources required to quickly conceive the stable isotope labeled standard for Lenacapavir. Thanks to its solid know-how, Alsachim was able to respond efficiently to the needs of its clients, thus proving its involvement and support against HIV.
Lenacapavir approval against HIV
Recently, the EMA issued a positive opinion on the use of Lenacapavir, also called Sulenca. The FDA also approved its market release in December 2022 (read the article).
Developed by Gilead Science, Lenacapavir is referred to as an inhibitor of the HIV capsid, which is the layer that protects the virus' DNA. Acting on the stability and transport of the complexes forming it, the drug inhibits several steps essential to the replication of the virus.
Combined with one or more antiretrovirals, this treatment offers a new hope to adults with multi-drug resistant HIV-1 infection. Lenacapavir has a long half-life, which means that it remains active in the body for several weeks. As a result, for the medicine to be efficient/effective, only two injections are required annually (read the press release).
Contributing to health improvement for over 15 years, Alsachim is pleased to provide a new anti-HIV product to its catalogue: the [13C,2H3]-Lenacapavir.
Learn more about the product and ask for a quote:
Share this news
Search on news
- 2023 (4)
- 2022 (4)
- 2021 (4)
- 2020 (11)
- 2019 (4)
- 2018 (1)
- 2017 (1)